论文部分内容阅读
目的:探讨MDR1基因多态性与乳腺癌患者化疗疗效以及血液毒副反应的关系。方法:筛选70例新辅助化疗的女性患者,利用PCR-RFLP技术检测其外周血MDR1C3435T基因型,分析不同基因型患者化疗后的疗效及血液毒副反应。结果:70例新辅助化疗患者当中,3435TT基因型化疗有效率仅为23.1%,与3435CC和3435CT基因型相比差异有统计学意义(χ2=6.122,P=0.047,95%CI:0.043～0.051);血液毒性方面,3435CC型患者中性粒细胞Ⅲ～Ⅳ度减少的发生率为6.7%,较CT型(37.5%)和TT型(53.8%)发生率低(χ2=7.512,P=0.023,95%CI:0.016～0.021)。结论:携带MDR1 3435C等位基因的患者其化疗疗效可能较好;携带3435T等位基因的患者其中性粒细胞减少的风险可能较高。
Objective: To investigate the relationship between MDR1 gene polymorphism and chemotherapy efficacy and side effects of blood in breast cancer patients. Methods: Seventy patients with neoadjuvant chemotherapy were screened. The genotypes of MDR1C3435T in peripheral blood were detected by PCR-RFLP. The curative effect and blood toxicity of different genotypes of patients after chemotherapy were analyzed. Results: The effective rate of 3435TT genotype chemotherapy in 70 neoadjuvant chemotherapy patients was only 23.1%, which was significantly different from 3435CC and 3435CT genotypes (χ2 = 6.122, P = 0.047, 95% CI: 0.043 ~ 0.051 ). In hematologic toxicity, the incidence of grade Ⅲ ~ Ⅳ neutrophil granulocytopenia in type 3435CC patients was 6.7%, which was lower than that of CT type (37.5%) and TT type (53.8%) (χ2 = 7.512, P = 0.023 , 95% CI: 0.016 ~ 0.021). CONCLUSIONS: Patients who carry the MDR1 3435C allele may be better treated with chemotherapy; patients with the 3435T allele may have a higher risk of neutropenia.